Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Andreessen Horowitz (a16z)
BioCentury | Jan 14, 2025
Finance
How VCs at the AI-bio interface set up their portfolios for success
Some firms are playing an active role in overcoming data starvation and bolstering the infrastructure ecosystem
BioCentury | Jan 13, 2025
Deals
Quick exit for Idrx shareholders as GSK pays $1B to get GIST asset
Early clinical data show efficacy signals that appear to improve on existing therapies in GI cancer settings
BioCentury | Oct 11, 2024
Finance
Upstream catches aftermarket updraft, as Camp4 IPO gets muted reception
BioCentury’s weekly Public Equity Report also includes financings by Crinetics, Scholar Rock, Immatics, Inhibikase and Vicore
BioCentury | Oct 11, 2024
Finance
City is location of Maraganore’s next RNAi play
BioCentury’s latest Venture Report includes rounds for Judo, Purespring, Basecamp, Arda and more
BioCentury | Sep 19, 2024
Finance
Series A cash for Brenus, GCTx, Nura among week’s VC highlights
Also in BioCentury’s latest Venture Report: New investment initiatives from Novo and RA Capital
BioCentury | Sep 19, 2024
Emerging Company Profile
GCTx: Simplifying iPSC-based cell therapy production
Launching with $75M, Cambridge, Mass. start-up aims to shortcut the cell therapy manufacturing process by directly activating transcription factors involved in cell fate
BioCentury | Sep 12, 2024
Regulation
Industry calls on FDA to clarify, expand platform tech program
Comments on the agency’s guidance document include requests that it extend the designation to platforms that have yet to yield an approved drug
BioCentury | Jun 28, 2024
Finance
Venture Report: Curie.Bio’s fund; megarounds for Formation, EvolutionaryScale, BillionToOne
Plus: New fundings for Exsilio, TwoStep and Augustine
BioCentury | Jun 13, 2024
Emerging Company Profile
Santa Ana: Leveraging human multi-omic data for precision immunology
Versant-founded immunology play launches with $168M to create biologics targeted to specific cell types
BioCentury | Apr 24, 2024
Deals
AI-guided antibody designer BigHat taps J&J as latest partner as internal pipeline advances
Still years away from the clinic, the biotech now has four deals with larger pharmas that are informing decisions around its wholly-owned programs
Items per page:
1 - 10 of 88